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There is evidence linking sphingolipid abnormalities, APP processing, and neuronal death in Alzheimer’s disease (AD). We
previously reported a strong elevation of ceramide levels in the brain of the APPSL/PS1Ki mouse model of AD, preceding the
neuronal death. To extend these ﬁndings, we analyzed ceramide and related-sphingolipid contents in brain from two other
mouse models (i.e., APPSL and APPSL/PS1M146L) in which the time-course of pathology is closer to that seen in most currently
available models. Conversely to our previous work, ceramides did not accumulate in disease-associated brain regions (cortex and
hippocampus) from both models. However, the APPSL/PS1Ki model is unique for its drastic neuronal loss coinciding with strong
accumulation of neurotoxic Aβ isoforms, not observed in other animal models of AD. Since there are neither neuronal loss nor
toxic Aβ species accumulation in APPSL mice, we hypothesized that it might explain the lack of ceramide accumulation,at least in
this model.
1.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia in adults. Pathologically, the hallmarks of AD are
amyloid plaques and neuroﬁbrillary tangles, associated with
widespread neuronal loss. Its fundamental causes and the
pathological cascades leading to symptoms, however, remain
poorly understood. Lipids and lipid peroxidation products
have important roles in central nervous system homeostasis.
Extensive evidence supports an important role of cholesterol
in the development and possibly progression of AD [1–3].
The role of other lipids, such as ceramides and related-
sphingolipids, (sphingomyelins, sulfatides, and glycosphin-
golipids)isalsoemerging.Ceramidesarethecoreconstituent
of most sphingolipids. They can be produced by hydrolysis
of sphingomyelin (SM) via sphingomyelinases (SMases) or
synthesized de novo from fatty acyl CoA and sphingosine.
Conversely, in the Golgi, ceramides may be transformed
into SM by the addition of phosphorylcholine. Additionally,
glycosyltransferases can attach sugar to ceramide, turning it
into glucosylceramide or galactosylceramide (Galcer), a key
step in the generation of complex glycosphingolipids [4, 5].
Ceramides are important second messenger molecules
that regulate diverse cellular processes including cell growth,
diﬀerentiation, and apoptosis. Ceramide levels also increase
in response to aging and various age-related stress factors
andaredirectlyinvolvedinapoptoticsignalinginvariouscell
types, including neurons [6–8].
There is evidence linking sphingolipid abnormalities,
APP processing, and neuronal death in AD. In vitro, it
has been shown that β-amyloid added to cultured neurons
[9, 10] or oligodendrocytes [11] increase SMase activity,
leading to an increase in ceramide levels [12]. Additional
reports have found that ceramide levels increase β-amyloid
synthesis [12, 13] and favor gamma secretase processing
of APP [14–16] so that inhibition of ceramide synthesis2 International Journal of Alzheimer’s Disease
confers protection against β-amyloid [9]. Thus, it has been
suggested that ceramides and β-amyloid may synergize to
induce neuronal death.
Several studies have examined the sphingolipid alter-
ations in human AD brain. For example, the total phos-
pholipid and sulfatide content in AD was decreased as
compared to normal [17–19], while the ceramide and
galactosylceramide levels were elevated [9, 18]. Enhanced
ceramide levels have been reported in the cerebrospinal
ﬂuid (CSF) of patients with AD [20]a n dc h a n g e si nt h e
activity of several key enzymes of ceramide metabolism,
in gene expression of pathways associated to sphingolipid
metabolism have been found in brains of AD patients [21,
22].
During the last years, numerous mouse transgenic lines
have beencreated and havebeen screened for various aspects
of AD pathology [23, 24]. Unfortunately, very little work has
been done on determining if sphingolipid content is likewise
perturbed in these rodent models of AD. In one study, long-
chain ceramides were shown to be elevated in presenilin
1 (PS1M146V) mouse brain and to induce apoptosis in
PS1 astrocytes [25]. In a second study, sulfatides, a class of
sulfated galactocerebrosides, were found to be decreased in
brain tissues from two APP transgenic mice (i.e., APPV717F
and APPsw), whereas no signiﬁcant changes in the content
of other sphingolipid classes including SM, Galcer, and
ceramides were noted [26]. By contrast, using the new
mouse mutant APPSL/PS1Knock-in line, we have recently
found an early and signiﬁcant increase of ceramides in the
cortex of these mice, without signiﬁcant changes in other
sphingolipid levels [27]. However, the APPSL/PS1Ki model
is unique for its drastic neuronal loss, not observed in other
animal models of AD [28]. The discrepancy in the few data
available and the lack of knowledge of sphingolipid levels
in the brain of other rodent models of AD prompted us to
investigate whether the sphingolipid composition is altered
in the brain of two other mouse models of AD: single APPSL
and double APPSL/PS1M146L transgenics. Concentrations of
ceramides, SM, Galcer, and sulfatides were determined in
three brain regions: the cortex and the hippocampus, the
two brain regions typically associated with the disease, and
the cerebellum, a nonvulnerable region with no Aβ plaques.
For all analyses, age-matched PS1M146L (amyloid free) mice
as well as nontransgenic wild-type mice (WT) were used.
2.Materialsand Methods
2.1. Chemicals. All organic solvents were of analytical
grade and came from VWR International (Strasbourg,
France). HPTLC-plates Silicagel 60, 10 × 10- or 10 ×
20cm were purchased from Merck (VWR International).
Lipid standards (nonhydroxy fatty acid (NFA) containing
ceramides, ceramides containing 2-hydroxy fatty acids (2-
HFA), sphingomyelins, cerebroside sulfate (sulfatides), and
galactosylceramides (a mixture containing 2-hydroxy fatty
acids and nonhydroxy fatty acids) were purchased from
Sigma-Aldrich (France). Aminopropyl-bonded (LC-NH2)
silica gel cartridges (100mg matrix) were from Supelco
(Saint Quentin Fallavier, France).
2.2. Transgenic Mice. Generation and detailed neuropatho-
logical analyses of the APPSL and the APPSL/PS1M146L
transgenic mice have been described earlier [29, 30]. In
brief, these mice express human APP751 with Swedish
and London mutations (Thy1 promoter) either alone or
in combination with human presenilin-1 (M146L, HMG-
CoA promoter). In this study, 12-month-old (n = 5)
APPSL/PS1M146L double transgenic, 12-month-old (n = 5)
PS1M146L single-transgenic littermates, and 12-month-old
(n = 6) nontransgenic mice as well as 24 month-old
(n = 5) APPSL single transgenic and 24-months (n = 5)
nontransgenic littermates were used (generous gift of Sanoﬁ-
Aventis, Vitry sur Seine, France). APPSL mice were analyzed
at 24 months of age and APPSL/PS1M146L mice were assessed
at 12 months of age because they revealed comparable levels
of amyloid plaques in the brain at these respective ages. The
genetic background of the mice was mixed CBA/C57BL/6.
All the mice used in this study were female, because a gender
eﬀect with female mice displaying more severe pathology
than male has been mentioned in several studies [27, 31, 32].
All experiments were performed in compliance and
following approval of the Sanoﬁ-Aventis Animal Care and
Use Committee and in accordance with standards of the
guide for the care and use of laboratory animals (CNRS
ILAR)and with respect toFrench and European Community
rules.
2.3. Brain Tissue Preparation. T h em i c ew e r ea n e s t h e t i z e d
withpentobarbital (40mg/kg,IP) and sacriﬁced. Brainswere
removed immediately, and cortex, hippocampus, and cere-
bellum were dissected. These cerebral regions were homog-
enized by 10 up-and-down strokes of a prechilled Teﬂon-
glass homogenizer in 20 volumesof buﬀer(25mM Tris-HCl,
150mM NaCl,1mM EDTA,pH7.4)and supplementedwith
50mM sodium ﬂuoride, 1mM phenylmethylsulfonyl ﬂuo-
ride, protease, and phosphatase inhibitor cocktails (50μL/g
tissue and 10μL/mL lysis buﬀer, resp.). The homogenates
were centrifuged at 15,000g for 15min at 4◦C. The resulting
pellet was resuspended in 3 volumes of ice-cold water,
altogether 1.5mL, homogenized at 4◦C (10–15 strokes) and
then sonicated for 20s using a soniﬁer (Branson Ultrasonics,
soniﬁer 450, Danbury, CT). Samples from each mouse brain
were analyzed separately and in duplicate.
2.4. Lipid Extraction fromTissues and Thin-Layer Chromatog-
raphy. Total lipids from brain homogenates were prepared
according to previously described procedures [27, 33].
Brieﬂy, the homogenates were added to 8vol. of rapidly
stirring methanol, then 4vol. of chloroform were added.
The mixture was stirred overnight, and then centrifuged
at 1,000g for 10min. The pellet was re-extracted with
chloroform-methanol-water (4:8:3, v/v/v) and the two
supernatants combined, evaporated to dryness. Partitioning
was carried out using diisopropyl ether/1-butanol/50mM
aqueous NaCl (6:4:5, v/v/v) according to the method
of Ladish and Gillard [34]. The total upper phase was
evaporated to dryness and taken up in chloroform. The
lipids were fractionated using solid-phase extraction onInternational Journal of Alzheimer’s Disease 3
100mg LC-NH2 cartridges (Supelco, L’Isle d’Abeau, France)
aspreviouslydescribed[27].Theelutedfractions containing,
respectively, free ceramides, galactosylceramides (Galcer),
alkali-stablephospholipids(SM),and sulfatideswere applied
to HPTLC plates with a Linomat 5 (Camag, Switzerland).
Prior to SM analysis, the phospholipid-containing fraction
was subjected to mild alkaline methanolysis (treatment with
chloroform: 0.6N NaOH in methanol 1:1 (v/v) at room
temperature for 1h) to remove glycerophospholipids. To
quantify each lipid species (ceramides, SM, Galcer, and
sulfatides), calibration curves were obtained by running in
parallel known amounts of puriﬁed lipid standards. For
free ceramides, 15–20mg of brain tissue (wet weight) was
spottedperlane.Theplatesweredevelopedwithchloroform-
methanol 50:3 (v/v) and visualized by charring for 10min
at 180◦C with 3% cupric acetate in 8% phosphoric acid
solution. For SM analysis, 6–9mg of tissue was spotted per
lane. The plates were developed with chloroform-methanol-
water 60:35:8 (v/v/v).SM was visualized with sulfuric acid-
CuSO4-ammonium molybdate spray reagent followed by
heating at 110◦C for 15min. Galcer and sulfatides (about
0.4mg and 2mg of tissue per lane, resp.) were developed
in chloroform-methanol-water 65:25:4 (v/v/v), sprayed
with orcinol-H2SO4 reagent, and then heated at 150◦Cf o r
2min.
Each sphingolipid species was quantiﬁed by scanning
densitometry of the plates at 396nm for ceramides, 540nm
forGalcer andsulfatides, and 750nm for SMwiththeCamag
TLC Scanner 3/WinCats software system.
2.5. Statistical Analysis. The results were presented as mean
± S.D. values. Owing to the small number of animals per
group, statistical analysis of the data was performed using
a nonparametric Kruskall-Wallis test followed by a posthoc
test of Dunn for multiple comparisons. For the comparison
of two means, the Mann-Whitney test was used. All cal-
culations were performed using GraphPad Prism software
3.02 (GraphPad Software, Inc.). P values less than .05 were
considered as signiﬁcant.
3.Results
In single APPSL mice (Figure 1(a)), a moderate but not
signiﬁcant elevationofNFA-ceramideswasseeninthecortex
(+22%), with no changes of the 2-HFA-ceramide level.
Conversely, in the hippocampus (Figure 1(b)), the NFA-
ceramide level did not diﬀer between WT and APPSL mice,
whereas a tendency towards an increase of 2-HFA-ceramides
was noted (+19%), although it was not signiﬁcant.
Surprisingly, as shown in Figure 1(c), the levelof 2-HFA-
ceramides in the cerebellum of APPSL mice was signiﬁcantly
increased in comparison to the counterpart of their WT
littermates (+50%, P<. 05). Conversely, the NFA-ceramides
showed a slight but not signiﬁcant decrease compared to
WT control values. However, no diﬀerence in the total
ceramide content was noticed in the cerebellum of both WT
(51.35 ± 1.45nmol/mg tissue) and APPSL mice (50.28 ±
3.31nmol/mg tissue).
Because the double-transgenic mouse model APPSL/
PS1M146L develops neuropathological features of AD earlier
than the single APPSL mice [29], the sphingolipid analysis
was performed in the brain regions of this model in younger
animals (12 months of age). As shown in Figures 2(a) and
2(b), concentrations of NFA-ceramides as well as those of 2-
HFA-ceramides did not diﬀer between wild-type, PS1M146L,
and APPSL/PS1M146L mice in the two disease-associated
brain regions (cortex and hippocampus). In contrast to the
changes of ceramide content in cerebellum of APPSL mice,
the NFA-ceramide as well as the 2-HFA-ceramide levels
were unchanged in this brain region in APPSL/PS1M146L
mice relative to their WT controls and PS1 littermates
(Figure 2(c)). However, NFA-ceramide content showed a
tendency towards a decrease, while 2-HFA ceramides tended
to slightly increase in the cerebellum of the APPSL/PS1M146L
mice.
It should be noted that, although cortex and hippocam-
pus of WT mice displayed almost identical ceramide content
(Figures 1(a), 1(b), 2(a), and 2(b)), a relatively lower NFA-
ceramide content was manifest in the cerebellum (Figures
1(c) and 2(c)). In normal human brain, the ceramide levels
were also reported much higher in the cortex versus the
cerebellum [18].
Typical ceramide proﬁles from either cortex, hippocam-
pus, or cerebellum of the diﬀerent transgenic mice and
wild-type controls were shown in Figure 3.S i n c e2 - H F A -
ceramides are present in extremely low levels leading to a
weak staining on the HPTLC plate, densitometric scanning
of the plate was shown to visualize the peak corresponding
to the 2-HFA-ceramide species (Figure 3).
To test whether other related-sphingolipids could be
altered in the brain of transgenic mice, the content of
SM, Galcer, and sulfatides in lipid extracts of the three
examined brain regions was assessed by HPTLC analysis.
Figures 1(d)–1(f) show that sphingolipids (SM, Galcer, and
sulfatides) did not display signiﬁcant changes in both cortex,
hippocampus, and cerebellum of APPSL mice compared to
the WT littermates. Similarly, the levels of SM, Galcer, and
sulfatides did not diﬀer among nontransgenic, PS1M146L and
APPSL/PS1M146L mice in all brain region examined (Figures
2(d)–2(f)). It should be noted that there are diﬀerences of
SM, Galcer, and sulfatide concentrations between cerebral
tissues (cortex and hippocampus) and cerebellar tissues. In
both models, cerebellum displayed higher levels of Galcer
and sulfatides than cerebral tissues. This is in accordance
with Cheng et al. [26]w h oa l s or e p o r t e da∼2-fold higher
level of sulfatides in the cerebellum compared to the cortex,
intwoothertransgenicmouse modelsofAD.Incontrast,SM
levels were almost identical in hippocampus and cerebellum,
but higher than those of cerebral cortex (Figures 1(d)–1(f)
and 2(d)–2(f)). Examples of HPTLC proﬁles of sulfatides,
Galcer, and SM and from either cortex, hippocampus, or
cerebellum were represented in Figures 4(a), 4(b),a n d4(c),
respectively. It should be mentioned that the HPTLC proﬁles
of each sphingolipid class were similar in all examined brain
regions from both mouse models.4 International Journal of Alzheimer’s Disease
4.Discussion
Using the same methodology as in our previous work
[27], we herein analysed the sphingolipid composition
of two additional models (i.e., single APPSL and double
APPSL/PS1M146L mice)inwhich thetime-courseofpathology
is much closer to that seen in the majority of currently
available models. The main results of this study are (1)
a moderate but not signiﬁcant increase of NFA-ceramides
and 2-HFA-ceramides in the cortex and the hippocampus
respectively, of the APPSL mice, (2) unaltered ceramide
levels in the two disease-associated brain regions from
APPSL/PS1M146L mice, (3) unexpected alterations of the
ceramide proﬁle in the cerebellum of APPSL mice, a region
with no Aβ pathology, and (4) no signiﬁcant changes
in the other related-sphingolipids in all brain structures
examined of both transgenic models. Based on our results
and those from the literature, we will ﬁrst discuss the
possibility of a relationship between neurodegeneration,
toxicAβaccumulation,andceramidecontent.Forthesecond
time, why an amyloid-free brain region such as cerebellum
showed ceramide alterations is discussed.
Ceramides were shown to accumulate in AD human
brainregions andtheirlevelsvary bydisease severitysuggest-
ing that they could be indicators of AD progression [9, 18,
35]. Similarly to what happens in human AD, we previously
found that ceramides increase very early in the cortex of
the APPSL/PS1Ki mouse model, preceding the neuronal loss
[27]. By contrast, our present results reveal that in single
APPSL mice, ceramide levels were not signiﬁcantly altered
in disease-associated brain regions (e.g., hippocampus or
cortex). This is consistent with the ﬁndings of Cheng et al.
[26] who reported no changes in ceramide content in any
brain region from APPsw and APPV717F transgenic mice.
An important diﬀerence between these single APP mouse
lines and the APPSL/PS1Ki model is that the latter develops
an early and massive neuronal loss which correlates with
strong accumulation of intracellular Aβ42, Aβ aggregates,
and Aβ42 oligomers [28, 36]. Although intraneuronal Aβ
accumulation has also been documented in various APP
models [29, 37, 38], a striking diﬀerence between the models
used in the present study and the APPSL/PS1Ki mice is
t h en a t u r eo ft h eA β peptides which accumulate. Indeed,
in APPSL/PS1Ki mouse brain, extremely high levels of N-
truncated Aβx-42 variants and abundant oligomers were
detected, which closely resembles that found in AD brain. By
contrast, in APPSL mouse brain, with the same totalAβ levels
as in APPSL/PS1Ki mice, only very limited levels of Aβ42
N-terminal truncated isovariants were detected [28]. In the
APPSL/PS1Ki mice, Aβx-42 is the major form accumulated
with a ratio Aβx-42/total Aβ close to 1. In comparison, this
ratio is approximately of only 0.2-0.3 in the APPSL mice,
and ∼0.3-0.4 in the double transgenic APPSL/PS1M146L mice,
similar to the range of values reported for a large number of
other APP-based transgenics [28, 29].
N-truncated Aβ peptides are known to aggregate more
readily and are considered to be very toxic species. Thus
they might play a key role in the neurotoxicity observed
in the APPSL/PS1Ki model. In particular, the pyroglutamate
modiﬁed N-terminal truncated form of Aβ at position 3
(Aβ3(pE)-42), which represents a major species in the brain
of AD patients [39], was recently shown to induce a severe
neuron loss in the TBA2 mouse model, a new model
expressing only N-truncated Aβ3(pE)-42 in neurons [40].
Interestingly, there is also a coincidence of considerable
amounts of Aβ3(pE)-42 and massive neuron loss in the
APPSL/PS1Ki mouse model [41]. On the basis of these
ﬁndings, it is attractive to speculate that in APPSL/PS1Ki
mice, the strong accumulation of intracellular toxic forms of
Aβ induces early elevation of ceramides. Extensive increase
of ceramidescouldtherefore activate proapoptotic pathways,
leading to neuronal death. Conversely, other APP transgenic
mouse models including the APPSL mice have been reported
to show no [42]o rv e r yl o wA β3(pE)-42 levels [43]. This is
due to the lack of posttranslational modiﬁcations such as N-
terminal degradation and pyroglutamyl formation in these
mice. Because APPSL mice display neither neuronal loss nor
accumulation of highly toxic Aβ 42 isoforms, this may at
least in part explain why no signiﬁcant accumulation of
ceramides occurredin the disease-associated brain regions of
these mice.
Thus, despitenumerous neuropathological,biochemical,
and even behavioral changes representative of AD developed
by these APP mice [23, 28–30, 33, 44], they may not
constitute a relevant model to further explore the role
of ceramides in AD pathology. However, answering the
question of the relationship between neurodegeneration,
toxic Aβ accumulation, and ceramide elevation could be
facilitated using restricted models either lacking (i.e., single
APP mice) or mimicking only some speciﬁc AD-related
neuropathological alterations (i.e., TBA2 mice mentioned
above). Indeed, owing to the simultaneous occurrence of
numerous pathological features of AD, the connection
between them is often diﬃcult to unravel.
We next determined the ceramide content in the double
transgenic mouse model APPSL/PS1M146L, but in younger
animals because the APPSL/PS1M146L mice develop neu-
ropathological features of AD earlier than single APPSL mice
[29]. At 12 months of age, these double transgenics revealed
comparable levels of amyloid deposits than 24-month-old
APPSL mice. Additionally, they displayed similar ganglioside
alterations [33]. Our results showed that at 12 months
of age, ceramide levels were unaltered in both cortex and
hippocampus ofAPPSL/PS1M146L mice in comparison to age-
matched PS1M146L mice and wild-type controls. It should
be noted that there is no neuronal loss in these mice as
old as 17 months, but unfortunately, older APPSL/PS1M146L
m i c ew e r en o ta v a i l a b l ef o rt h i ss t u d y .H o w e v e r ,i no u r
previous work, we demonstrated that elevation of ceramides
occurred very early (3 months of age) in the cortex of
the APPSL/PS1Ki model, preceding by far the neuronal loss
detectable at 6 months of age. Why the APPSL/PS1Ki mice
showed an increase of ceramides several months before the
appearance of neuronal death while the APPSL/PS1M146L
micedidnotiscurrentlyunknown.Onepossibleexplanation
isthattheneuronallossreported intheAPPSL/PS1M146L mice
is moderate and more restricted than in the APPSL/PS1Ki
model. Indeed, the loss of neurons in the former involvesInternational Journal of Alzheimer’s Disease 5
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Figure 1: Levels of NFA-ceramides and 2-HFA-ceramides (a–c) and other related-sphingolipids (SM, GalCer, and sulfatides) (d–f) in the
cortex, hippocampus,andcerebellum of24-month-oldAPPSL miceandage-matchednontransgenicmice.WT:wild-type controlmice.Each
sphingolipid class was analyzed by HPTLC and their respective concentrations were calculated from standard curves after densitometric
scanning of the plates as described under Section 2. Values are expressed as the means ± S.D. and statistically analyzed by a Mann-Whitney
test. ∗P<. 05 compared to the respective wild-type mice.
only the hippocampal pyramidal cell layer (loss of ∼30%
in 17-month-old animals). This may in some way account
for the lack of ceramide accumulation in the cortex of these
mice.Bycomparison,in theAPPSL/PS1Kimodel,thecellloss
is greater (∼50% at 10 months of age) and has been shown
to extend to other brain areas such as frontal cortex [36]
and cholinergic system [45]. Moreover, as discussed above,
accumulationof N-truncated Aβ peptidesshould be lesser in
APPSL/PS1M146L mice, since the ratio Aβx-42/total Aβ is of
0.3 only, versus 1 in the APPSL/PS1Ki mice. In this context,
it would seem likely that the level of highly toxic Aβ3(pE)-42
form, which is thought to be involved in neuronal death, is
reducedintheAPPSL/PS1M146L model.It is also possible that,
at 12 months of age, it is too early to visualize an elevation of
ceramides, owing to the slowest progression of AD lesions
in these mice than in the APPSL/PS1Ki model. Since we did
not have older APPSL/PS1M146L mice, we should therefore be
cautious to interpret the results of ceramide composition in
t h e s em i c e ,b e c a u s ew ec a n n o te x c l u d et h ep o s s i b i l i t yt h a t
ceramides increase at a later age. Further investigations on
this topic are warranted.
The most unexpected ﬁnding of the present study was
alteration of the ceramide composition in the cerebellum
of APPSL mice, a brain region lacking Aβ deposits and
regarded as nonvulnerable to the disease. Intriguingly, we
noted a signiﬁcant increase of 2-HFA-ceramides (+50%)
which was concomitant with a slight decrease in NFA-
ceramides. However, considering the total ceramide content,6 International Journal of Alzheimer’s Disease
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Figure 2: Levels of NFA-ceramides and 2-HFA-ceramides (a–c) and other related-sphingolipids (SM, GalCer, and sulfatides) (d–f) in the
cortex, hippocampus, and cerebellum of 12-month-old APPSL/PS1M146L,P S 1 M146L mice, and age-matched nontransgenic mice. WT: wild-
type control mice. Each sphingolipid class was analyzed by HPTLC and their respective concentrations were calculated from standard
curves after densitometric scanning of the plates as described under Section 2. Values are expressed as the means ± S.D. There was no
signiﬁcant diﬀerence in all sphingolipid levels between wild-type (WT), PS1M146L,a n dA P P SL/PS1M146L mice in either cortex, hippocampus,
or cerebellum (Dunn’s multiple comparison test following a Kruskall-Wallis test).
it was almost similar between wild-type and APPSL mice.
Previously, we found a more dramatic 161% increase of
2-HFA-ceramides in the cortex of APPSL/PS1Ki mice but
contrary to the present results, it was accompanied by an
elevation of NFA-ceramides.
Hydroxy FA-ceramides are relatively minor species of
membrane lipids. As evident from the literature, the cur-
rent knowledge about the metabolism and physiological
function of 2-HFA-ceramides is very limited. In particular
in AD studies, no attention was paid to 2-HFA-ceramides,
rendering it very diﬃcult to draw conclusions about the
role of these ceramide species in AD physiopathology.
Nevertheless, a couple of interesting facts suggest that these
HFA species may participate to AD pathology: (i) it was
recently found that Aβ selectively bound to sphingolipids
that contained a 2-OH group on the ceramide backbone and
did not eﬀectively interact with sphingolipids that contained
a nonhydroxylated fatty acid, favoring a conformational shift
that disrupts membrane stability and promotes peptide-
peptide interactions and oligomer formation [46]; (ii)
the enzyme UDP-galactose: ceramide galactosyltransferase
(CGT), which transfers galactose to both NFA- and 2-HFA-
ceramides, was found to be upregulated in human AD brain
[21]. Interestingly, overexpression of CGT in transgenic
mice led to a reversal NFA:HFA-Galcer ratio which resulted
in both decrease in HFA-Galcer and increase in NFA-
Galcer levels [47]. Reducing the HFA-Galcer level would
lead to an accumulation of their immediate precursors, 2-
HFA-ceramides; (iii) there is some evidence for enhanced
apoptosis-inducing activity of 2-HFA-ceramides comparedInternational Journal of Alzheimer’s Disease 7
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Figure 3:Typical HPTLCproﬁles ofceramides from hippocampus of12-month-oldAPPSL/PS1M146L,PS1 M146L, andtheir age-matched wild-
type (WT) control mice (a), and from cerebral cortex and cerebellum of 24-month-old APPSL mice and age-matched WT control ((b) and
(c), resp.). The densitometric analyses of the HPTLC plates were shown in parallel, respectively. Std: a mixture of standard NFA-ceramides
and 2-HFA-ceramides. Ceramides were developed on HPTLC plates with chloroform-methanol (50:3) and located by spraying the plate
with copper acetate 3% in H3PO4 8% reagent, followed by heating. Both 2-HFA-Cer and NFA-Cer appear as two bands corresponding
to long-chain ceramides (≥22C; upper band) and short-chain ceramides (≤18C; lower band). Quantitative evaluation of ceramides was
performed by scanningthe plate at 396 nm with the Camag TLC Scanner 3/WinCats software system.
to NFA-ceramides [48], and this eﬀect seems to be cell type
speciﬁc. In this sight, mouse mutants with defective saposin
D dramatically accumulate HFA-ceramides in cerebellum,
resulting in a selective loss of cerebellar Purkinje cells [49];
(iv) we reported a gender-speciﬁc expression of HFA- versus
NFA-ceramides in the APPSL/PS1Ki mouse model of AD,
and this biochemical feature could be related to the increase
propensity of females to develop earlier neuronal loss [27].
Although the degree of 2-HFA-ceramide accumulation
in the cerebellum of APPSL mice is much lesser than that
seen in the cortex of the APPSL/PS1Ki mice, the reasons for
these biochemical changes in this amyloid-free brain area8 International Journal of Alzheimer’s Disease
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Figure 4: Examples of HPTLC proﬁles of sphingolipids from diﬀerent brain regions of nontransgenic and transgenic mice. (a)
Sulfatides from cerebral cortex of 12-month-old APPSL/PS1M146L,P S 1 M146L, and their age-matched wild-type (WT) control mice. (b)
Galactosylceramides (GalCer) from hippocampus of 24-month-old APPSL mice and age-matched WT control mice. Galcer and sulfatides
were developed in chloroform-methanol-water (65:25:4), sprayed with orcinol-H2SO4 reagent, and then heated. Both Galcer and
sulfatides∗ appear as two bands corresponding to the 2-HFA- (lower band) and NFA-containing galactolipids (upper band), respectively.
∗Standard sulfatides from bovine brain resolved in three bands, as a result of diﬀerent fatty acid chain length. (c) Sphingomyelins (SM)
from cerebellum of 24-month-old APPSL mice and age-matched WT control mice; SMs were developed with chloroform-methanol-water
(60:35:8) (v/v/v) and visualized with sulfuric acid –CuSO4-ammonium molybdate spray reagent followed by heating. SMs appear as two
bands which result of the diﬀerences in the fatty acid chain length. Std: standard sulfatides, GalCer, and SM, respectively.
are currently unknown. Possibly, it might reﬂect alterations
of ceramide metabolism, since there is evidence that other
metabolic pathways are perturbed in the cerebellum of
t h e s em i c e[ 50]. Hydroxy FA sphingolipids are synthesized
by the same set of enzymes as nonhydroxy sphingolipids,
except for fatty acid 2-hydroxylase (FA2H). The expression
of FA2H is highly variable among cell types and is inducible
by certain stimuli [48]. One may speculate that, upon
unknown signal, 2-HFA-ceramides may be preferentially
synthesized instead of NFA-species. Abnormal degradation
ofHFAsphingolipidsmaybealsopossible.Ithasbeenshown
that galactosylceramidase, which forms 2-HFA-ceramides
from Galcer is up-regulated, whereas acid ceramidase which
hydrolyzed 2-HFA-ceramides into HFA and sphingosine
is down-regulated in human AD brain [21]. Thus, with
combinatorialup-anddown-regulation ofenzymesinvolved
in sphingolipid metabolism, the cell could modify the levels
of 2-HFA-ceramides in response to the changing cellular
environment. However, this is highly speculative and further
investigation is warranted todeterminewhether thesefactors
or other unknown factors contribute to such changes of the
ceramide proﬁle in the APPSL cerebellum. It should be noted
that also intriguing is the substantial elevation of ceramide
reported by Han et al. [18] in the cerebellum of AD patients;
this point also remains to be clariﬁed.
In this study, we also examined the content of other
ceramide-related sphingolipid classes including SM, Gal-
cer, and sulfatides. Similarly to what we observed in the
APPSL/PS1Ki model, we did not found any changes of SM
and galactolipid levels in all brain regions from the two
transgenic lines investigated. Similar ﬁndings were seen in
APPsw and APPV717F transgenic mice, respectively, except
for sulfatides [26]. Indeed, by contrast to our results, a loss
of sulfatide content was observed in multiple brain regions
of these animals. The reasons for such discrepancies are
s t i l lu n c l e a r ,b u ti tm a yb ea s c r i b e dt ot h ed i ﬀerent genetic
background of mouse lines and/or the genetic constructs
based on diﬀerent APP mutation and diﬀerent promoters.
Supporting this, it has been shown for example, that APPSL
transgenic and wildtype mice on C57BL/6 background have
lower basal cholesterol levels than the Ki mouse lines which
are on C57BL/6 50%-CBA 25%-129SV 25% background
[44]. Another example is the diﬀerence of lipid composition
reported by Sawamura and coworkers [15] between mouse
lines with C57BL/6J and FVB/N backgrounds, respectively.
Moreover, theseauthors foundthatPS2transgenic micewith
C57BL/6J background displayed signiﬁcant phospholipid
alterations, particularly of SM, as compared to their wild-
type controls, while PS2 transgenic mice with FVB/N
background did not. These few examples point out the
diﬃculties to compare the results from various mouse lines
and reinforce the idea that additional studies in this ﬁeld are
required.
5.Conclusion
I ns u m m a r y ,t h i ss t u d ye x t e n d sp r e v i o u so b s e r v a t i o n so n
sphingolipid alterations in animal models of AD. Despite
several limitations, in particular the lack of old double
transgenics, the present results demonstrated that, in the
absence of neurodegeneration, no elevation of ceramides
occurred in disease-aﬀected brain regions from single APPSL
mice, thus corroborating recent ﬁndings in two other single
APP mice [26]. Moreover, since both neuronal loss and
accumulation of toxic N-truncated Aβ peptides are lacking
in the APPSL model, this might suggest that Aβ-inducedInternational Journal of Alzheimer’s Disease 9
ceramide production is an important event leading to
neuronal death. In the future, to support this hypothesis, it
will be interesting toanalyse the sphingolipidcomposition of
the TBA2 mice, the new model expressing only N-truncated
Aβ3(pE)-42 and which develops a severe neuronal loss [40],
to evaluate whether or not ceramides, especially the 2-OH
species, accumulate in the brain of these mice.
Accumulating and crossing the information obtained
from various animal models will help to better understand
the exact mechanism by which these sphingolipids con-
tribute to AD pathogenesis.
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